{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:42:58Z","timestamp":1789764178078,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","award":["BioMarin Pharmaceutical"],"award-info":[{"award-number":["BioMarin Pharmaceutical"]}],"id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","award":["Amicus Therapeutics"],"award-info":[{"award-number":["Amicus Therapeutics"]}],"id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013394","name":"REGENXBIO","doi-asserted-by":"publisher","award":["REGENXBIO"],"award-info":[{"award-number":["REGENXBIO"]}],"id":[{"id":"10.13039\/100013394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004264","name":"Robert Luff Foundation","doi-asserted-by":"publisher","award":["Robert Luff Foundation"],"award-info":[{"award-number":["Robert Luff Foundation"]}],"id":[{"id":"10.13039\/501100004264","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Frognal Trust","award":["The Frognal Trust"],"award-info":[{"award-number":["The Frognal Trust"]}]},{"name":"The Catherine Cookson Charitable Trust","award":["The Catherine Cookson Charitable Trust"],"award-info":[{"award-number":["The Catherine Cookson Charitable Trust"]}]},{"name":"The Sir Samuel Scott of Yews Trust","award":["The Sir Samuel Scott of Yews Trust"],"award-info":[{"award-number":["The Sir Samuel Scott of Yews Trust"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, are a group of inherited neurodegenerative disorders that mostly arise in childhood. Each of the NCLs is a genetically distinct disease caused by variants in at least 13 different genes (\n                      <jats:italic>CLN1\u2013CLN14<\/jats:italic>\n                      ). NCLs are neurodegenerative, and symptoms can include a combination of childhood dementia, epileptic seizures, motor decline and vision loss, and eventually lead to premature death. There is currently no cure for any subtype of NCL, however, enzyme replacement therapy is available for CLN2 disease, and several treatment strategies are being explored for other NCL subtypes. Early diagnosis and initiation of supportive services (e.g. health, education, social services) are essential to preserve quality of life. Only a few studies have investigated family experiences with NCL, many of which are international in scope.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A mixed-method research study was conducted in the UK to understand family experiences in CLN2 and CLN3 disease. It involved an initial literature review, followed by in-depth qualitative interviews. Interview data were analysed using a thematic analysis. Thirteen families (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913) participated in the interviews. This represented 16 parents (11 mothers and 5 fathers) of 18 children (10 diagnosed with CLN3 disease and 8 diagnosed with CLN2 disease). Findings were analysed jointly across CLN2 and CLN3 disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six overarching themes emerged from the analysis: difficulty in recognising early symptoms; the shock of a diagnosis; the demands of caring for complex and ever-changing needs; a constant battle to access appropriate and timely support services; the extensive impact on the unaffected sibling; and the all-encompassing impact on the family.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study contributes novel UK specific data on family experiences and unmet needs in CLN2 and CLN3 disease. More needs to be done to ensure NCLs are diagnosed early, and timely local support services are made available to protect quality of life for both the affected children and their families.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03747-8","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T02:32:47Z","timestamp":1747017167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evidence of the impact of CLN2 and CLN3 Batten disease on families in the United Kingdom"],"prefix":"10.1186","volume":"20","author":[{"given":"Sara E.","family":"Mole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6553-9647","authenticated-orcid":false,"given":"Shannon","family":"Nordstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Wait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilda","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Brownnutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Gibbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kenrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Sisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Nightingale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"2","key":"3747_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","volume":"79","author":"RE Williams","year":"2012","unstructured":"Williams RE, Mole SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology. 2012;79(2):183\u201391.","journal-title":"Neurology"},{"key":"3747_CR2","unstructured":"National Institute of Neurological Disorders and Stoke. Neuronal Ceroid Lipofuscinosis (Batten Disease): NIH. 2024 [updated 11\/01\/2024. Available from: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/neuronal-ceroid-lipofuscinosis-batten-disease#:~:text=Researchers%20supported%20by%20NINDS%20have,common%20form%20of%20Batten%20disease"},{"issue":"11","key":"3747_CR3","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.bbadis.2012.08.012","volume":"1832","author":"M Haltia","year":"2013","unstructured":"Haltia M, Goebel HH. The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim Biophys Acta. 2013;1832(11):1795\u2013800.","journal-title":"Biochim Biophys Acta"},{"key":"3747_CR4","doi-asserted-by":"publisher","first-page":"754045","DOI":"10.3389\/fneur.2021.754045","volume":"12","author":"E Gardner","year":"2021","unstructured":"Gardner E, Mole SE. The genetic basis of phenotypic heterogeneity in the neuronal ceroid lipofuscinoses. Front Neurol. 2021;12:754045.","journal-title":"Front Neurol"},{"issue":"5","key":"3747_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/adc.2009.173419","volume":"95","author":"C Verity","year":"2010","unstructured":"Verity C, Winstone AM, Stellitano L, Will R, Nicoll A. The epidemiology of progressive intellectual and neurological deterioration in childhood. Arch Dis Child. 2010;95(5):361\u20134.","journal-title":"Arch Dis Child"},{"key":"3747_CR6","unstructured":"The Batten Disease Family Association. About Batten Disease: Batten Disease Family Association. 2024 [Available from: https:\/\/www.bdfa-uk.org.uk\/batten-disease\/what-is-batten-disease"},{"key":"3747_CR7","unstructured":"The Batten Disease Family Association. CLN3 Disease (Juvenile Batten Disease): Batten Disease Family Association. 2022 [Available from: https:\/\/www.bdfa-uk.org.uk\/batten-disease\/types-batten-disease\/cln3"},{"key":"3747_CR8","unstructured":"The Batten Disease Family Association. CLN2 disease, late-infantile Online: Batten Disease Family Association. 2024 [07\/04\/2022]. Available from: https:\/\/www.bdfa-uk.org.uk\/batten-disease\/types-batten-disease\/cln2"},{"key":"3747_CR9","unstructured":"Batten Disease Family Association, Disease CLN. Late-Infantile 2017 [Available from: https:\/\/www.bdfa-uk.org.uk\/batten-disease\/types-batten-disease\/cln2"},{"key":"3747_CR10","doi-asserted-by":"crossref","unstructured":"Schulz A, Kohlsch\u00fctter A, Mink J, Simonati A, Williams R. NCL diseases - clinical perspectives. Biochim Biophys Acta. 2013(11):1801\u20136.","DOI":"10.1016\/j.bbadis.2013.04.008"},{"issue":"9","key":"3747_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0883073813494268","volume":"28","author":"JW Mink","year":"2013","unstructured":"Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;28(9):1101\u20135.","journal-title":"J Child Neurol"},{"issue":"1","key":"3747_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","volume":"18","author":"SE Mole","year":"2019","unstructured":"Mole SE, Anderson G, Band HA, Berkovic SF, Cooper JD, Kleine Holthaus SM, et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 2019;18(1):107\u201316.","journal-title":"Lancet Neurol"},{"key":"3747_CR13","unstructured":"Batten Disease Family Association. Brineura for CLN2 2022 [Available from: https:\/\/www.bdfa-uk.org.uk\/research-treatment\/research-overview"},{"key":"3747_CR14","doi-asserted-by":"crossref","unstructured":"Kohlsch\u00fctter A, Schulz A, Bartsch U, Storch S. Current and emerging treatment strategies for neuronal ceroid lipofuscinoses. CNS Drugs. 2019(4):315\u201325.","DOI":"10.1007\/s40263-019-00620-8"},{"key":"3747_CR15","unstructured":"European Medicines Agency. Summary of Product Characteristics - Brineura 150\u00a0mg solution for infusion 2017 [updated 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/brineura-epar-product-information_en.pdf"},{"key":"3747_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/TCRM.S241048","volume":"16","author":"N Specchio","year":"2020","unstructured":"Specchio N, Pietrafusa N, Trivisano M. Changing times for CLN2 disease: the era of enzyme replacement therapy. Ther Clin Risk Manag. 2020;16:213\u201322.","journal-title":"Ther Clin Risk Manag"},{"key":"3747_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"8","author":"N Nickel","year":"2018","unstructured":"Nickel N, Simonati A, Jacoby D, Lezius S, Kilian D, Van de Graaf B, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;8:582\u201390.","journal-title":"Lancet Child Adolesc Health"},{"issue":"7","key":"3747_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.bbadis.2015.03.007","volume":"1852","author":"A Kohlsch\u00fctter","year":"2015","unstructured":"Kohlsch\u00fctter A, Riga C, Crespo D, Torres JM, Penchaszadeh V, Schulz A. Ethical issues with artificial nutrition of children with degenerative brain diseases. Biochim Biophys Acta. 2015;1852(7):1253\u20136.","journal-title":"Biochim Biophys Acta"},{"issue":"23","key":"3747_CR19","doi-asserted-by":"publisher","first-page":"e2436","DOI":"10.1212\/WNL.0000000000009454","volume":"94","author":"MC Masten","year":"2020","unstructured":"Masten MC, Williams JD, Vermilion J, Adams HR, Vierhile A, Collins A, et al. The CLN3 disease staging system: A new tool for clinical research in Batten disease. Neurology. 2020;94(23):e2436\u201340.","journal-title":"Neurology"},{"key":"3747_CR20","unstructured":"The Beyond Batten Disease Foundation. What is Batten disease? Beyond Batten Disease Foundation; 2022 [Available from: https:\/\/beyondbatten.org\/understanding-batten\/what-is-batten\/#:~:text=CLN3%2C%20often%20called%20juvenile%20Batten,progressive%20vision%20loss%20becomes%20noticeable"},{"key":"3747_CR21","first-page":"73","volume":"6","author":"JR Ostergaard","year":"2016","unstructured":"Ostergaard JR. Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights. Degener Neurol Neuromuscul Dis. 2016;6:73\u201383.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"4","key":"3747_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.oret.2019.11.005","volume":"4","author":"GA Wright","year":"2020","unstructured":"Wright GA, Georgiou M, Robson AG, Ali N, Kalhoro A, Holthaus SK, et al. Juvenile Batten disease (CLN3): detailed ocular phenotype, novel observations, delayed diagnosis, masquerades, and prospects for therapy. Ophthalmol Retina. 2020;4(4):433\u201345.","journal-title":"Ophthalmol Retina"},{"key":"3747_CR23","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/S1090-3798(15)30402-5","volume":"19","author":"A Schulz","year":"2015","unstructured":"Schulz A, Miller N, Mole SE, Cohen-Pfeffer JL. P89\u20132878: neuronal ceroid lipofuscinosis-2 (CLN2) natural history and path to diagnosis: international experts\u2019 current experience and recommendations on CLN2 disease, a type of Batten disease, resulting from TPP1 enzyme deficiency. Eur J Pediatr Neurol. 2015;19:S119.","journal-title":"Eur J Pediatr Neurol"},{"key":"3747_CR24","doi-asserted-by":"crossref","unstructured":"Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los Reyes E, Denecke J et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017:102\u201312.","DOI":"10.1016\/j.pediatrneurol.2017.01.034"},{"key":"3747_CR25","unstructured":"Devereux G, Stellitano L, Verity CM, Nicoll A, Will RG, Rogers P. Variations in neurodegenerative disease across the UK: findings from the National study of progressive intellectual and neurological deterioration (PIND). Arch Dis Child. 2004(1):8\u201312."},{"issue":"1","key":"3747_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13023-021-01813-5","volume":"16","author":"SE Mole","year":"2021","unstructured":"Mole SE, Schulz A, Badoe E, Berkovic SF, de Los Reyes EC, Dulz S, et al. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J Rare Dis. 2021;16(1):185.","journal-title":"Orphanet J Rare Dis"},{"key":"3747_CR27","doi-asserted-by":"crossref","unstructured":"Schulz A, Jain M, Butt T, Ballinger R, Eliasson L, Macey J et al. The challenges of living with and caring for a child or children affected by neuronal ceroid lipofuscinosis type 2 disease: In-Depth family surveys in the united Kingdom and Germany. J inborn errors metab screen. 2020.","DOI":"10.1590\/2326-4594-jiems-2019-0013"},{"key":"3747_CR28","doi-asserted-by":"crossref","unstructured":"Krantz M, Malm E, Darin N, Sofou K, Savvidou A, Reilly C, Bostr\u00f6m P. Parental experiences of having a child with CLN3 disease (juvenile Batten disease) and how these experiences relate to family resilience. Child Care Health Dev. 2022;n\/a(n\/a).","DOI":"10.1111\/cch.12993"},{"issue":"3","key":"3747_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/1367493513485825","volume":"18","author":"C Malcolm","year":"2014","unstructured":"Malcolm C, Gibson F, Adams S, Anderson G, Forbat L. A relational Understanding of sibling experiences of children with rare life-limiting conditions: findings from a qualitative study. J Child Health Care. 2014;18(3):230\u201340.","journal-title":"J Child Health Care"},{"issue":"1","key":"3747_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13023-024-03119-8","volume":"19","author":"A Schulz","year":"2024","unstructured":"Schulz A, Patel N, Brudvig JJ, Stehr F, Weimer JM, Augustine EF. The parent and family impact of CLN3 disease: an observational survey-based study. Orphanet J Rare Dis. 2024;19(1):125.","journal-title":"Orphanet J Rare Dis"},{"key":"3747_CR31","doi-asserted-by":"crossref","unstructured":"Cozart EJ, Augustine EF, Mink JW, Thatcher AR, Adams HR. (Batten disease and parents: marital quality, support, and communication. J Int Child Neurol Association 2017;1.","DOI":"10.17724\/jicna.2017.114"},{"key":"3747_CR32","doi-asserted-by":"crossref","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007(6):349\u201357.","DOI":"10.1093\/intqhc\/mzm042"},{"key":"3747_CR33","doi-asserted-by":"crossref","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. 2006:77\u2013101.","DOI":"10.1191\/1478088706qp063oa"},{"issue":"9","key":"3747_CR34","doi-asserted-by":"publisher","first-page":"165480","DOI":"10.1016\/j.bbadis.2019.05.016","volume":"1866","author":"B Elmerskog","year":"2020","unstructured":"Elmerskog B, T\u00f8ssebro AG, Atkinson R, Rokne S, Cole B, Ockelford A, Adams HR. Overview of advances in educational and social supports for young persons with NCL disorders. Biochim Biophys Acta Mol Basis Dis. 2020;1866(9):165480.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3747_CR35","unstructured":"The King\u2019s Fund. Public satisfaction with the NHS and social care in 2022 Online: The King\u2019s Fund. 2023 [17\/03\/2024]. Available from: https:\/\/www.kingsfund.org.uk\/insight-and-analysis\/reports\/public-satisfaction-nhs-and-social-care-2022"},{"issue":"11","key":"3747_CR36","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.bbadis.2013.02.017","volume":"1832","author":"S von Tetzchner","year":"2013","unstructured":"von Tetzchner S, Fosse P, Elmerskog B. Juvenile neuronal ceroid lipofuscinosis and education. Biochim Biophys Acta. 2013;1832(11):1894\u2013905.","journal-title":"Biochim Biophys Acta"},{"key":"3747_CR37","unstructured":"National Institute for Health and Care Excellence (NICE). Epilepsies in children. Young People Adults Online; 2025 27\/04\/2022."},{"issue":"2","key":"3747_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10545-018-0143-x","volume":"41","author":"WFE Kuper","year":"2018","unstructured":"Kuper WFE, van Alfen C, Rigterink RH, Fuchs SA, van Genderen MM, van Hasselt PM. Timing of cognitive decline in CLN3 disease. J Inherit Metab Dis. 2018;41(2):257\u201361.","journal-title":"J Inherit Metab Dis"},{"key":"3747_CR39","unstructured":"Government of the United Kingdom. Newborn blood spot screening: programme handbook: GOV.IL. 2024 [17\/03\/2024]. Available from: https:\/\/www.gov.uk\/government\/publications\/health-professional-handbook-newborn-blood-spot-screening\/7-conditions#inherited-metabolic-diseases"},{"issue":"1","key":"3747_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13023-017-0622-4","volume":"12","author":"Y Zurynski","year":"2017","unstructured":"Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, et al. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12(1):68.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3747_CR41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13023-022-02561-w","volume":"17","author":"K Sandilands","year":"2022","unstructured":"Sandilands K, Williams A, Rylands AJ. Carer burden in rare inherited diseases: a literature review and conceptual model. Orphanet J Rare Dis. 2022;17(1):428.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3747_CR42","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10826-024-02790-6","volume":"33","author":"JC Atkins","year":"2024","unstructured":"Atkins JC, Padgett CR. Living with a rare disease: psychosocial impacts for parents and family Members\u2013 a systematic review. J Child Fam Stud. 2024;33(2):617\u201336.","journal-title":"J Child Fam Stud"},{"key":"3747_CR43","unstructured":"European Commission. Norway - Sickness benefit and attendance allowance Online: European Commission. 2024 [08\/03\/2024]. Available from: https:\/\/ec.europa.eu\/social\/main.jsp?catId=1123%26langId=en%26intPageId=4706#:~:text=Attendance%20allowance%20can%20be%20provided,allowance%20at%20the%20same%20time"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03747-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03747-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03747-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T08:42:25Z","timestamp":1750149745000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03747-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3747"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03747-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"References have been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the British Healthcare Business Intelligence Association\u2019s Legal & Ethical Guidelines for Market Research. The study was non-interventional, with subjects recruited via the BDFA. All participants provided written consent before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.W. is an employee and S.N. is a consultant at The Health Policy Partnership Ltd, the organisation which received funding to conduct this research and draft the manuscript from the BDFA. P.G. has received payments to his institution as a study site according to clinical trial budget and honoraria and travel support from BioMarin Pharmaceutical. F.G. has received fees for advisory boards and travel grants from BioMarin Pharmaceutical.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}